<div class="qMYqUG_convSearchResultHighlightRoot">
<div class="" data-turn-id-container="request-WEB:358025a4-babd-4cd5-8368-0989249581f5-4" data-is-intersecting="true">
<section class="text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:358025a4-babd-4cd5-8368-0989249581f5-4" data-turn-id-container="request-WEB:358025a4-babd-4cd5-8368-0989249581f5-4" data-testid="conversation-turn-10" data-turn="assistant">
<div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)">
<div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn" data-conversation-screenshot-content="">
<div class="flex max-w-full flex-col gap-4 grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" dir="auto" tabindex="0" data-message-author-role="assistant" data-message-id="b889d53a-36fb-4739-ae44-5127c67b0f7b" data-message-model-slug="gpt-5-5" data-turn-start-message="true">
<div class="flex w-full flex-col gap-1 empty:hidden">
<div class="markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling">
<p class="PDq2pG_selectionAnchorContainer" data-start="0" data-end="125">Model: 4-week-old <span class="hover:entity-accent entity-underline inline cursor-pointer align-baseline"><span class="whitespace-normal">SM/J</span></span> mice (with <span class="hover:entity-accent entity-underline inline cursor-pointer align-baseline"><span class="whitespace-normal">C57BL/6J</span></span> comparison mice)</p>
<p data-start="127" data-end="279" data-is-last-node="" data-is-only-node="">Dosage: Weekly intraperitoneal injections of 40 mg/kg Navitoclax or 5 mg/kg Dasatinib + 50 mg/kg Quercetin from 4 to 6–8 or 17 weeks of age.</p>
</div>
</div>
</div>
</div>
<div class="z-0 flex min-h-[46px] justify-start"></div>
<div class="mt-3 w-full empty:hidden">
<div class="text-center"></div>
</div>
</div>
</div>
</section>
</div>
</div>
<div class="pointer-events-none -mt-px h-px translate-y-[calc(var(--scroll-root-safe-area-inset-bottom)-14*var(--spacing))]" aria-hidden="true"></div>


Dasatinib and Quercetin Delay Early-Onset Disc Degeneration in Mice

Researchers find that clearing senescent cells preserves disc structure and slows early-onset disc degeneration in mice.


Aging &amp; Longevity

<p><strong data-start="26" data-end="36">Model:</strong> Older adults (60–85 years old) with mild cognitive impairment (MCI) enrolled in a randomized, double-blind, placebo-controlled clinical trial.</p>
<p><strong data-start="222" data-end="233">Dosage:</strong> Participants received one gastro-resistant capsule daily for 180 days, containing either 250 mg of <em data-start="339" data-end="363">Kluyveromyces fragilis</em> yeast extract, 350 mg of <em data-start="393" data-end="419">Saccharomyces cerevisiae</em> yeast extract, or a placebo.</p>


Yeast Supplement Improves Cognitive Function in Older Adults with Mild Cognitive Impairment

Daily supplementation with nucleotide-rich yeast extracts improves cognitive performance and mental well-being in older adults with mild cognitive impairment, researchers find. 

Brain &amp; Neurons

<p><span style="font-weight: 400;">Model: 5xFAD mouse model for Alzheimer’s disease </span></p>
<p><span style="font-weight: 400;">Dosage: Oral administration of 457 mg/kg/day of glucosamine for 2 weeks </span></p>


Supplementing with glucosamine, a compound found in our cartilage, increases the risk of mortality from dementia in certain individuals while also worsening memory in mice that model dementia. 

Study led by Dr. Ramon Sun on the far right (image: mbi.ufl.edu). 

<p>Model: Six adults who received intravenous NAD+ and eight adults who received intravenous NR</p>
<p>Dosage: 500 mg of intravenous NAD+ or 500 mg of intravenous NR daily for four consecutive days</p>


Pilot Human Study Supports Safety of NAD+ IV and NR IV Infusions

A Stanford study supports the short-term safety of NAD+ and NR infusion therapies, and participants who received NR infusions exhibited significantly lower HbA1c (a blood test that reflects average blood sugar over two to three months).

(An IV bag containing a solution with NAD+ | Crete Fertility Centre)

A Stanford human trial provides the first data supporting the safety of NAD+ IV and NR IV therapies.

The NAD+ (nicotinamide adenine dinucleotide) precursor NR (nicotinamide riboside) counters sleep-deprivation-induced cognitive deficits in rats with excess Alzheimer’s plaques. 


Search Result: research findings

Dasatinib and Quercetin Delay Early-Onset Disc Degeneration in Mice

Yeast Supplement Improves Cognitive Function in Older Adults with Mild Cognitive Impairment

Common Joint Health Supplement May Progress Dementia, New Study Finds

Pilot Human Study Supports Safety of NAD+ IV and NR IV Infusions

NAD+ Booster Counters Cognitive Deficits of Sleep Deprivation, New Study Shows